Constipation Clinical Trial
Official title:
Mechanism of Action of Biofeedback Therapy
Verified date | June 2017 |
Source | Augusta University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Biofeedback therapy improves bowel symptoms and anorectal function in patients with
dyssynergic defecation, however its mechanism of action is not known. The investigators
hypothesize that biofeedback therapy enhances gut-brain-gut communication by altering
cortical processing of information and improving cortically mediated neuromuscular function
of the gut. The investigators' specific aims are; (1) To evaluate the afferent cortical
evoked potentials in response to the electrical stimulation of the anorectum (i) before and
after biofeedback therapy and (ii) compare responders with nonresponders. (2) To evaluate the
corticofugal tracts (efferent) by recording the anal and rectal electromyographic responses
following noninvasive lumbosacral and transcranial magnetic stimulation (i) before and after
biofeedback therapy and (ii) compare responders with nonresponders.
The investigators hypothesize that biofeedback therapy enhances gut-brain-gut communication
and alters cortical and neuromuscular function. The investigators' specific aims are to
evaluate 60 patients with dyssynergia (i) before and after biofeedback therapy and (ii)
compare responders with nonresponders by examining:
(A) The afferent cortical evoked potentials using electrical stimulation of the anus and
rectum.
(B) The efferent cortical evoked potentials by lumbosacral and transcranial magnetic
stimulation and recording the anal and rectal electromyographic responses.
Status | Completed |
Enrollment | 50 |
Est. completion date | January 2016 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - During the previous year, all patients must have experienced or reported at least two of the following symptoms for at least three months and with 25% of bowel movements (when not taking laxatives) (22):1) stool frequency of less than three/week, 2) passage of hard stools, 3) excessive straining, 4) a feeling of incomplete evacuation, 5)sensation of anorectal obstruction or blockage and 6) use of manual maneuvers to facilitate defecations (e.g., digital evacuation). - No evidence of structural disease (excluded by colonoscopy/ b. enema and metabolic problem by lab tests. - Patients on stable doses of antidepressants without anticholinergic effects will be included. - Patient must be undergoing biofeedback treatment - Patient must be right-handed Exclusion Criteria: - Patients taking drugs that are constipating, (e.g.; calcium channel antagonists will either be excluded or drug discontinued) - Patients with comorbid illnesses; severe cardiac disease, chronic renal failure or previous gastrointestinal surgery except cholecystectomy and appendectomy. - Neurologic diseases e.g.; head injury.epilepsy,multiple sclerosis, strokes, spinal cord injuries. - Impaired cognizance (mini mental score of < 15) and/or legally blind. - Pregnant or likely to conceive during the course of the study. Women with potential for pregnancy must be willing to use contraceptive measures during the study. Urinary pregnancy tests will be performed on such women prior to any radiologic procedures. - Hirschsprung's disease. - Alternating constipation and diarrhea (78). - Ulcerative and Crohns colitis. - Previous pelvic surgery, rectocele repair, bladder repair, radical hysterectomy. - Rectal prolapse or anal fissure or anal surgery. - Presence of metal in the skull, cranial cavity, back or hips. - People who have a cardiac pacemaker, an implanted defibrillator, or a medication pump. |
Country | Name | City | State |
---|---|---|---|
United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
Lead Sponsor | Collaborator |
---|---|
Augusta University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the afferent cortical evoked potentials using electrical stimulation of the anus and rectum (i) before and after biofeedback therapy and (ii) compare responders with nonresponders. | 2 visits of 3 hours each (3 months between 1st and 2nd visit) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 | |
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 |